mTORC1 is hyperactive in LKB1/KRAS mutant lung adenocarcinoma cancer cells and, thus, targeting this pathway by mTOR inhibitors might represent an effective way of treating lung adenocarcinoma [340,341]. Here, KRAS is linked to cancer.